Plantar Fasciitis Treatment Market Size, Share, Industry, Forecast and outlook (2024-2031)

Plantar Fasciitis Treatment Market is segmented By Treatment Type (Surgery, Shockwave Therapy (Extracorporeal Shock Wave Therapy (ESWT), Intracorporeal Pneumatic Shockwave Therapy (IPST)), Medication Therapy (Analgesics (), Nonsteroidal Anti-inflammatory Drugs (NSAIDs) (Ibuprofen (Advil, Excedrin IB, Motrin, Ibuprin), Ketoprofen (Actron, Orudis, Oruvail), Naproxen (Aleve, Anaprox, Naprelan, Naprosyn)), Others), Orthotics, Other treatments), By End-User (Hospitals, Orthopedic Clinics, Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031

Report Overveiw

The Plantar Fasciitis Treatment Market is expected to grow at a CAGR of 4.2% during the forecast period (2024-2031). 

Plantar fasciitis is an inflammation of the plantar fascia which is a fibrous band of tissue on the bottom of the foot which supports the arch. It occurs when this band of tissue is overloaded or overstretched. This causes small tears in the fibers of the fascia, especially where the fascia meets the heel bone. Plantar fasciitis is common in obese people and pregnant women, their extra body weight overloads the delicate plantar fascia. It is also common in people with diabetes, although the exact reason for this is unknown.

As per DataM Intelligence, Plantar Fasciitis Treatment Market study analysis offers an in-depth outlook on the market containing quantitative and qualitative data. It gives an outlook and forecast of the global market based on market segmentation. It also provides global Plantar Fasciitis Treatment Market size, and growth, along with the latest trends, opportunities, and forecast till 2029 for the global market with esteem to major countries such as the United States, Canada, Brazil, Germany, Italy, Spain, United Kingdom, Russia, European countries, United Arab Emirates, Saudi Arabia, South Africa, Japan, China, India, South Korea, Australia, and rest of the countries over the globe.

Among all regions, the North American region is expected to hold the largest share of the global market over the forecast period. Plantar Fasciitis Treatment Market in the United States and Canada produces the utmost share. Whereas the European Plantar Fasciitis Treatment Market is projected to continue its presence globally during the period of 2024-2031.

Plantar Fasciitis Treatment Market Scope

For More Insights Request Free Sample

Plantar Fasciitis Treatment Market Dynamics

The increasing number of plantar fasciitis cases is expected to drive the plantar fasciitis treatment market growth over the forecast period

Increasing adoption of orthotics techniques coupled with rising cases of plantar fasciitis is among the major factors driving the market growth globally. As per the National Center for Health Statistics (NCHS), it is estimated that about two million population suffers from plantar fasciitis annually worldwide. Incorrect walking posture, a sudden rise in sports activities, prolonged standing, weight-bearing, and ill-fitted shoes can trigger micro-tears in the plantar fascia, and result in plantar fasciitis.

Increasing incidences of obesity are also expected to drive plantar fasciitis treatment market growth

Geriatric. and obese people are more prone to plantar fasciitis. It leads to sharp pain and other complications, in which, plantar fascia, a tissue connecting the heel and the toe bones becomes less flexible and more constrained.

As per the World Health Organization (WHO), in 2016, more than 1.9 billion adults, 18 years and older, were overweight. Of these over 650 million were obese. 39% of adults aged 18 years and over were overweight in 2016, and 13% were obese. Most of the world's population lives in countries where overweight and obesity kill more people than underweight. Thirty-eight million children under the age of 5 were overweight or obese in 2019. Over 340 million children and adolescents aged 5-19 were overweight or obese in 2016.

An increase in the number of individuals living sedentary lifestyles along with changes in eating habits leads to a rise in obesity, which puts pressure on the joints and ankles and can result in plantar fasciitis.

The high cost of treatment is hampering the market growth

However, the high cost of the treatment and lack of awareness about the plantar fasciitis condition is hampering the growth of the market. Also, the lack of stable raw materials pricing for the production of effective therapeutic medical devices is expected to hinder the growth of the market. Some concerns regarding the decline in profitability ratio for the products amid the availability of large inventory and raw material stock with the manufacturers are expected to restrict the market growth.

Epidemiology

Plantar fasciitis is very common in the US, with millions experiencing heel pain every year. The cause of plantar fasciitis is multifactorial, but most cases result from overuse stress. It is estimated that over two million Americans seek treatment for plantar heel pain each year. The prevalence of active and military populations is especially high. Globally, in both athletic and nonathletic populations, the incidence of plantar fasciitis is reported to be approximately 10%.

The average age of a patient with proximal plantar fasciitis is around 45 years. There is also known sex-based dimorphism in presentation, with proximal plantar fasciitis being twice as common in women as in men.

Plantar fasciitis accounts for about 10% of runner-related injuries and 11% to 15% of all foot symptoms requiring professional medical care. It occurs in about 10% of the general population as well, with 83% of these patients being active working adults between the ages of 25 and 65 years old.

Plantar Fasciitis Treatment Market Segment Analysis

By treatment type, the global market is classified into medication therapy, orthotics, shockwave therapy, surgery, and others.

The orthotic devices segment is dominating the global plantar fasciitis treatment market over the forecast period

Orthotic devices, also known as orthoses, are the type of braces that supports weakened muscles while walking or running. These devices also improve comfort and slow down the progress of contractures. These can be worn at any time of the day or night. The use of an orthotic device depends on the patient’s type of concern. The common types of orthotic devices include knee-ankle-foot orthoses and ankle-foot orthoses.

Plantar fasciitis commonly occurs as a result of flattening of the foot, which makes the foot appear larger. One of the best ways to ease the burden on the foot is by essentially replacing the structure of the arch. Orthotics are a valuable solution for people struggling with the discomfort of plantar fasciitis. Hence, to reach consumer requirements, market players are focussing on developing different novel and technologically advanced orthotic devices which are anticipated to propel the overall market.

The Shockwave therapy segment of treatment type is expected to grow at the fastest CAGR over the forecast period

The shockwave therapy market is segmented into extracorporeal shock wave therapy and intracorporeal pneumatic shockwave therapy. Plantar fasciitis is growing due to increasing common foot pain conditions which has also raised the number of treatments globally. In Extracorporeal shock wave therapy, sound waves are directed at the area of heel pain to stimulate healing. It is commonly used for chronic plantar fasciitis that hasn't responded to more-conservative treatments. Some studies show promising results, but it isn't consistently effective.

Medication therapy is expected to grow significantly over the forecast period

Medication is useful in the early stages, especially if the patient has begun stretching exercises, because, initially, these can worsen the pain.

Some of the medications used for the treatment of plantar fasciitis are:

• Analgesics: Analgesics ensure patient comfort, promote pulmonary toilet, and have sedating properties, which are beneficial for patients who have sustained trauma or who have sustained injuries.
  • Acetaminophen (Aspirin Free Anacin, Fever all, Tylenol) is effective in relieving mild to moderate acute pain; however, it has no peripheral anti-inflammatory effects.
• Nonsteroidal Anti-inflammatory Drugs: NSAIDs have analgesic and antipyretic activities. They inhibit its leukotriene synthesis, lysosomal enzyme release, lipoxygenase activity, neutrophil aggregation, and various cell membrane functions.
  • Ibuprofen (Advil, Excedrin IB, Motrin, Ibuprin) are used for patients with mild to moderate pain. Inhibits inflammatory reactions and pain by decreasing prostaglandin synthesis.
  • Ketoprofen (Actron, Orudis, Oruvail): For the relief of mild to moderate pain and inflammation. Small initial dosages are indicated in small and elderly patients and those with renal or liver disease.
  • Naproxen (Aleve, Anaprox, Naprelan, Naprosyn): For the relief of mild to moderate pain; inhibits inflammatory reactions and pain by decreasing the activity of cyclooxygenase, which is responsible for prostaglandin synthesis. NSAIDs decrease intraglomerular pressure and decrease proteinuria.

By end-user, the market is segmented into hospitals, ambulatory surgical centers, clinics, and others.

Hospitals are contributing to the majority of the market share in the global market for plantar fasciitis treatment

The hospital's segment held the major share of the market in terms of revenue in 2019 due to the rising number of surgeries for treatment, which takes place in hospitals. Medication therapy has gained traction due to the most widely adopted line of therapy to manage symptoms related to plantar fasciitis like inflammation and pain. However, few people need surgery to detach the plantar fascia from the heel bone. Surgery is generally an option only when the pain is severe, and other treatments have failed. It can be done as an open procedure or through a small incision with local anesthesia.

Plantar Fasciitis Treatment Market Geographical Share

North America holds plantar fasciitis treatment accounted for the largest market share in 2019, and is expected to grow significantly over the forecast period, due to increasing investments in the development of new treatment options, a large population base with foot pain conditions, and expansion in the distribution networks. The prevalence rates of plantar fasciitis are growing rapidly in the United States. For instance, As per a Health and Wellness Survey report by Richard L Nahin et al., published in the Journal of Pain 2018, the estimated prevalence rate of plantar fasciitis in United States adults was highest among women (1.19%) compared to men (0.47%), in the population aged 45 to 64 (1.33%) versus population aged 18 to 44 (0.53%). Also, the rise in the number of obese people in the United States and changing lifestyle is driving the growth of the market. As per the National Clinical Trials (NCT) registry, as of June 18, 2020, currently, there are about 6 recruiting clinical trials across different phases of development for the treatment of Plantar Fasciitis in the United States.

Pipeline Analysis

March 2020: Revance Therapeutics Inc., has multiple therapeutic clinical trials for DAXI underway, including the JUNIPER Phase 2 trial in adult upper limb spasticity, ASPEN-1 Phase 3 study, and the ASPEN open-label safety study (OLS) in cervical dystonia, and a Phase 2 trial for plantar fasciitis. The ASPEN-1 and plantar fasciitis trials are fully enrolled with all subjects dosed and past the primary endpoint visit; enrollment for ASPEN-OLS is ongoing. Enrollment in the JUNIPER Phase 2 adult upper limb spasticity trial is paused due to challenges in subject assessments during the time of required social distancing. Revance is planning to report the results for the ASPEN-1 cervical dystonia and Phase 2 plantar fasciitis trials in 2H of 2020 and would provide additional updates as there is greater clarity.

COVID-19 Impact Analysis

With the COVID-19 outbreak in December 2019, the virus has spread globally to more than 100 countries with the World Health Organization, declaring it a public health emergency. The global impacts of COVID-19 are already starting to be felt and are expected to significantly affect the market in 2020. COVID-19 is affecting the global economy by directly affecting production and demand, disturbing the supply chain and market disruption, and by its a financial impact on firms and financial markets.

Plantar Fasciitis Treatment Market Companies and Competitive Landscape

The global market is consolidated. Several private companies are focusing on the development and introduction of novel products into the market, which is easily affordable and accessible. For instance, in 2017, BioElectronics Corporation received the USFDA approval of ActiPatch as drug-free pain therapy for plantar fasciitis and osteoarthritis.

The plantar fasciitis treatment market is moderately competitive and consists of several major players. Some of the key players which are contributing to the growth of the market include A. Algeo Limited, Superfeet Worldwide, Inc., Hanger, Inc., Bayer Group (Dr. Scholl's), GlaxoSmithKline Plc, Bauerfeind AG, Pfizer, Inc., Sanofi, and Ottobock SE & Co., KGaA. (Ottobock Holding), among others.

The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the market globally. For instance,

• Acquisition: In February 2017, Wiivv has raised USD 4 million in Series A funding and acquisition of eSoles which will enable the company to divulge into custom-fit footwear. This expansion of the organization will enable them to undergo greater innovations and propel them to establish themselves as the leader of custom-fit footwear. This acquisition gives Wiivv a database of around 50,000 3D foot scans which can help them produce insoles with high levels of accuracy

Pfizer, Inc.

Overview:

Pfizer is one of the world's premier innovative biopharmaceutical companies, discovering, developing, and providing over 170 different medicines and vaccines healthcare products to help improve the lives of millions of people in the UK and around the world every year.

Product Portfolio:

DEPO-MEDRONE® (METHYLPREDNISOLONE ACETATE) Depo-Madrone contains methylprednisolone acetate. Methylprednisolone belongs to a group of medicines called corticosteroids or steroids. Corticosteroids are produced naturally in your body and are important for many body functions.